Interventions for Tuberculosis Control and Elimination 2002

Table 3. Summary of adverse reactions from rifampicin with estimated frequencies
of occurrence. Note that these are estimates of frequencies which may vary
across population groups.
Frequent Common Infrequent Rare
(� 5 per 100) (� 1 per 100 and (� 1 per 1,000 (< 1 per 1,000)
< 5 per 100) and < 1 per 100)
Bilirubin elevations Hepatitis Interstitial nephritis
in the beginning Pruritus Glomerulonephritis
of treatment Flu syndrome Renal failure
Orange discoloration Drug fever Toxic epidermal
of urine and tears* necrolysis
Liver enzyme Oligomenorrhea
elevations Amenorrhea
Anaphylactic shock
Neutropenia
Leukopenia
Hemolytic anemia
Pseudomembranous
colitis
Eosinophilic colitis
Lupus erythematosus
Myopathy
* Not an adverse drug event, but a normal occurrence that might cause anxiety in patients.
��� ���� ���� ���������
�
�
�
�
���
�����
��� �
�����
32
��� �
�����
��� �
���
Figure 17. Hepatitis frequency following isoniazid alone or in combination with
rifampicin. 198